Chronic idiopathic constipation (CIC) is a common gastrointestinal disorder that is characterized by difficulty defecating, including hard stools and a sensation of incomplete evacuation or blockage. CIC can also be associated with abdominal pain and bloating that negatively impact patients’ QOL. The key treatment goals for CIC are improving bowel function and overall symptom relief. Once patients have failed OTC agents, such as bulk-forming laxatives (psyllium, methylcellulose) and osmotic therapies (polyethylene glycol, lactulose), they move to prescription drug therapy. The CIC drug market includes two guanylate cyclase-C agonists, Synergy’s Trulance and Allergan / Ironwood’s Linzess, and one bicyclic fatty acid, Mallinckrodt’s Amitiza. Most recently, Takeda’s Motegrity, a 5-HT4-receptor agonist, was approved for CIC.
- What percentage of CIC patients receive drug therapy within one year of diagnosis, and how quickly? What percentage of patients progress to later lines of therapy within one year of diagnosis?
- What patient shares do key therapies and brands garner by line of therapy in newly diagnosed CIC patients? What are the quarterly trends in prescribing among recently treated and newly diagnosed CIC patients?
- How has Motegrity been integrated into the treatment algorithm, and what is its source of business?
- What percentage of CIC patients are treated with monotherapy versus combination therapy? What are the most commonly used combinations?
- What are the product-level compliance and persistency rates among drug-treated patients?
Longitudinal patient-level claims data analysis
KEY DRUGS COVERED
Amitiza, Linzess, Motegrity, Trulance
KEY ANALYSIS PROVIDED
- Brand/therapy usage across a longitudinal patient sample.
- Newly diagnosed patient analysis.
- Treatment initiation and progression.
- Line of therapy analysis.
- Combination therapy analysis.
- Source of business for recently treated patients.
- Persistency and compliance analysis.
- Product-level patient flowcharts.
Treatment Algorithms: Claims Data Analysis provides detailed, quantitative analysis of the treatment journey and brand usage across lines of therapy and overall using real-world, patient-level claims data so that marketers can accurately assess their source of business, benchmark usage against competitors, and quantify areas of opportunity for their marketed or emerging brand.
- Chronic Idiopathic Constipation - Current Treatment - Detailed, Expanded Analysis: Treatment Algorithms: Claims Data Analysis (US)
Author(s): Mohit Nasa, MBA
Mohit Nasa is a Lead Insights analyst on the Immune and Inflammatory team at Decision Resources Group and has authored content for indications like asthma and rheumatoid arthritis.
He holds a Bachelor’s degree in Pharmacy and has earned his MBA in marketing and CRM from Amity Business School. Prior to joining DRG, Mohit worked as a Senior Business analyst at Novartis where he was responsible for end to end market assessment, reporting analytics and related projects for Novartis’s asthma brand Xolair. Mohit has also worked as Brand Manager at Ozone pharma and an Account Manager for IMS Health.